These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 19887134)

  • 21. Long-lasting protection of sheep against bluetongue challenge after vaccination with virus-like particles: evidence for homologous and partial heterologous protection.
    Roy P; Bishop DH; LeBlois H; Erasmus BJ
    Vaccine; 1994 Jul; 12(9):805-11. PubMed ID: 7975859
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of protection afforded by a bivalent virus-like particle vaccine against bluetongue virus serotypes 1 and 4 in sheep.
    Pérez de Diego AC; Athmaram TN; Stewart M; Rodríguez-Sánchez B; Sánchez-Vizcaíno JM; Noad R; Roy P
    PLoS One; 2011; 6(10):e26666. PubMed ID: 22046324
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genetically engineered multi-component virus-like particles as veterinary vaccines.
    Pearson LD; Roy P
    Immunol Cell Biol; 1993 Oct; 71 ( Pt 5)():381-9. PubMed ID: 8270267
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cell-mediated immune response and cross-protective efficacy of binary ethylenimine-inactivated bluetongue virus serotype-1 vaccine in sheep.
    Umeshappa CS; Singh KP; Pandey AB; Singh RP; Nanjundappa RH
    Vaccine; 2010 Mar; 28(13):2522-31. PubMed ID: 20117268
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The significance of the structural characteristics of the agent for the problems of immunization against blue tongue].
    Müller H
    Tierarztl Prax; 1991 Dec; 19(6):591-5. PubMed ID: 1665600
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats.
    Bréard E; Belbis G; Hamers C; Moulin V; Lilin T; Moreau F; Millemann Y; Montange C; Sailleau C; Durand B; Desprat A; Viarouge C; Hoffmann B; de Smit H; Goutebroze S; Hudelet P; Zientara S
    Vaccine; 2011 Mar; 29(13):2495-502. PubMed ID: 21256877
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An inactivated vaccine for the control of bluetongue virus serotype 16 infection in sheep in Italy.
    Savini G; Ronchi GF; Leone A; Ciarelli A; Migliaccio P; Franchi P; Mercante MT; Pini A
    Vet Microbiol; 2007 Sep; 124(1-2):140-6. PubMed ID: 17499459
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genetically engineered particulate virus-like structures and their use as vaccine delivery systems.
    Roy P
    Intervirology; 1996; 39(1-2):62-71. PubMed ID: 8957671
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Seroconversion, neutralising antibodies and protection in bluetongue serotype 8 vaccinated sheep.
    Oura CA; Wood JL; Sanders AJ; Bin-Tarif A; Henstock M; Edwards L; Floyd T; Simmons H; Batten CA
    Vaccine; 2009 Dec; 27(52):7326-30. PubMed ID: 19786141
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep.
    Eschbaumer M; Hoffmann B; König P; Teifke JP; Gethmann JM; Conraths FJ; Probst C; Mettenleiter TC; Beer M
    Vaccine; 2009 Jun; 27(31):4169-75. PubMed ID: 19406189
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Potency and efficacy of inactivated bluetongue virus vaccines.
    Stevens DR; Stott J; Osburn BI; Giles R; Wiesehahn GP; Barber TL
    Prog Clin Biol Res; 1985; 178():649-52. PubMed ID: 2989914
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A European field strain of bluetongue virus derived from two parental vaccine strains by genome segment reassortment.
    Batten CA; Maan S; Shaw AE; Maan NS; Mertens PP
    Virus Res; 2008 Oct; 137(1):56-63. PubMed ID: 18598726
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Generation of replication-defective virus-based vaccines that confer full protection in sheep against virulent bluetongue virus challenge.
    Matsuo E; Celma CC; Boyce M; Viarouge C; Sailleau C; Dubois E; Bréard E; Thiéry R; Zientara S; Roy P
    J Virol; 2011 Oct; 85(19):10213-21. PubMed ID: 21795358
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Colostral antibody protection and interference with immunity in lambs born from sheep vaccinated with an inactivated Bluetongue serotype 8 vaccine.
    Oura CA; Wood JL; Floyd T; Sanders AJ; Bin-Tarif A; Henstock M; Edwards L; Simmons H; Batten CA
    Vaccine; 2010 Mar; 28(15):2749-53. PubMed ID: 20123052
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Myxomavirus as a vector for the immunisation of sheep: protection study against challenge with bluetongue virus.
    Top S; Foucras G; Deplanche M; Rives G; Calvalido J; Comtet L; Bertagnoli S; Meyer G
    Vaccine; 2012 Feb; 30(9):1609-16. PubMed ID: 22244980
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of baculovirus expression vectors: development of diagnostic reagents, vaccines and morphological counterparts of bluetongue virus.
    Roy P
    FEMS Microbiol Immunol; 1990 Nov; 2(4):223-34. PubMed ID: 2178355
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of real-time RT-PCR as a rapid molecular approach for differentiation of field and vaccine strains of bluetongue virus serotypes 2 and 9.
    Elia G; Savini G; Decaro N; Martella V; Teodori L; Casaccia C; Di Gialleonardo L; Lorusso E; Caporale V; Buonavoglia C
    Mol Cell Probes; 2008 Feb; 22(1):38-46. PubMed ID: 17693055
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Heterologous prime boost vaccination with DNA and recombinant modified vaccinia virus Ankara protects IFNAR(-/-) mice against lethal bluetongue infection.
    Calvo-Pinilla E; Rodríguez-Calvo T; Sevilla N; Ortego J
    Vaccine; 2009 Dec; 28(2):437-45. PubMed ID: 19857449
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High-yield production of canine parvovirus virus-like particles in a baculovirus expression system.
    Jin H; Xia X; Liu B; Fu Y; Chen X; Wang H; Xia Z
    Arch Virol; 2016 Mar; 161(3):705-10. PubMed ID: 26666439
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of a quadrivalent modified-live bluetongue virus vaccine in wildlife species.
    McConnell S; Morrill JC; Livingston CW
    Prog Clin Biol Res; 1985; 178():631-8. PubMed ID: 2989912
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.